PDL BioPharma

PDLI NASDAQ
2.910
-0.070
-2.35%
盘后: 2.910 0 0.00% 16:23 06/14 EDT
开盘
2.980
昨收
2.980
最高
2.980
最低
2.900
成交量
74.42万
成交均量(3M)
124.28万
52周最高
3.890
52周最低
2.250
换手率
0.62%
市值
3.51亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供PDL BioPharma PDLI股票价格,PDL BioPharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
展开 >

最近浏览

名称
价格
涨跌幅